Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ANGO

ANGO - AngioDynamics Inc Stock Price, Fair Value and News

5.80USD-0.19 (-3.17%)Market Closed
Watchlist

Market Summary

USD5.80-0.19
Market Closed
-3.17%

ANGO Stock Price

View Fullscreen

ANGO RSI Chart

ANGO Valuation

Market Cap

231.2M

Price/Earnings (Trailing)

-16.38

Price/Sales (Trailing)

0.7

EV/EBITDA

8.32

Price/Free Cashflow

-36.25

ANGO Price/Sales (Trailing)

ANGO Profitability

EBT Margin

-2.82%

Return on Equity

-3.52%

Return on Assets

-2.83%

Free Cashflow Yield

-2.76%

ANGO Fundamentals

ANGO Revenue

Revenue (TTM)

329.5M

Rev. Growth (Yr)

-7.44%

Rev. Growth (Qtr)

0.5%

ANGO Earnings

Earnings (TTM)

-14.1M

Earnings Growth (Yr)

-242.3%

Earnings Growth (Qtr)

-163.31%

Breaking Down ANGO Revenue

Last 7 days

1.6%

Last 30 days

3.2%

Last 90 days

-9.2%

Trailing 12 Months

-52.2%

How does ANGO drawdown profile look like?

ANGO Financial Health

Current Ratio

2.38

Debt/Equity

0.12

Debt/Cashflow

-0.07

ANGO Investor Care

Shares Dilution (1Y)

1.84%

Diluted EPS (TTM)

-0.36

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023334.7M338.8M335.9M329.5M
2022306.1M316.2M320.8M327.9M
2021272.5M291.0M297.8M303.3M
2020277.0M264.2M268.3M271.1M
2019265.6M270.6M272.7M272.8M
2018282.4M261.7M260.7M264.1M
2017356.1M349.6M326.5M304.0M
2016351.2M353.9M358.2M358.0M
2015359.9M356.5M353.2M350.3M
2014360.1M360.1M359.9M359.9M
2013318.1M354.4M358.1M361.7M
2012220.2M221.8M251.0M281.5M
2011215.7M215.6M218.5M223.3M
20100216.0M215.9M215.8M

Tracking the Latest Insider Buys and Sells of AngioDynamics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jul 21, 2023
helsel dave
sold (taxes)
-3,157
8.65
-365
svp global operations and r&d
Jul 21, 2023
trowbridge stephen a
sold (taxes)
-5,769
8.65
-667
evp and cfo
Jul 21, 2023
clemmer james c
sold (taxes)
-29,167
8.65
-3,372
president and ceo
Jul 21, 2023
centea scott
sold (taxes)
-2,205
8.65
-255
svp/gm, vit
Jul 21, 2023
campbell chad thomas
sold (taxes)
-3,416
8.65
-395
svp/gm, vascular access
Jul 21, 2023
piccinini laura
sold (taxes)
-3,572
8.65
-413
svp international
Jul 20, 2023
campbell chad thomas
sold (taxes)
-3,137
8.74
-359
svp/gm, vascular access
Jul 20, 2023
clemmer james c
sold (taxes)
-26,062
8.74
-2,982
president and ceo
Jul 20, 2023
piccinini laura
sold (taxes)
-5,383
8.74
-616
svp international
Jul 20, 2023
centea scott
sold (taxes)
-2,910
8.74
-333
svp/gm, vit

1–10 of 50

Which funds bought or sold ANGO recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 20, 2024
Quarry LP
added
115
12,217
21,552
-%
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
reduced
-39.29
-531,000
990,000
0.08%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
19.87
54,000
243,000
-%
Feb 16, 2024
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO
added
21.42
139,066
600,066
-%
Feb 15, 2024
B. Riley Asset Management, LLC
unchanged
-
26,904
232,154
0.08%
Feb 15, 2024
Legal & General Group Plc
reduced
-84.12
-193,481
39,709
-%
Feb 15, 2024
State of Wyoming
added
37.33
42,141
131,257
0.02%
Feb 15, 2024
Farther Finance Advisors, LLC
new
-
3,716
3,716
-%
Feb 15, 2024
BARCLAYS PLC
added
131
412,000
692,000
-%
Feb 15, 2024
JANE STREET GROUP, LLC
reduced
-39.46
-163,518
302,663
-%

1–10 of 49

Are Funds Buying or Selling ANGO?

Are funds buying ANGO calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ANGO
No. of Funds

Unveiling AngioDynamics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
5.69%
2,268,461
SC 13G/A
Feb 09, 2024
dimensional fund advisors lp
3.7%
1,489,108
SC 13G/A
Jan 23, 2024
blackrock inc.
12.7%
5,044,098
SC 13G/A
Jan 23, 2024
millennium management llc
4.6%
1,835,777
SC 13G/A
Jan 22, 2024
state street corp
2.53%
1,009,307
SC 13G/A
Oct 06, 2023
blackrock inc.
10.5%
4,161,884
SC 13G/A
Sep 12, 2023
millennium management llc
5.2%
2,055,247
SC 13G
Jul 05, 2023
victory capital management inc
3.68%
1,445,045
SC 13G/A
Feb 10, 2023
dimensional fund advisors lp
6.9%
2,687,481
SC 13G/A
Feb 09, 2023
vanguard group inc
7.11%
2,781,793
SC 13G/A

Recent SEC filings of AngioDynamics Inc

View All Filings
Date Filed Form Type Document
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
8-K
Current Report
Feb 09, 2024
SC 13G/A
Major Ownership Report
Jan 23, 2024
SC 13G/A
Major Ownership Report
Jan 23, 2024
SC 13G/A
Major Ownership Report
Jan 22, 2024
SC 13G/A
Major Ownership Report
Jan 22, 2024
8-K
Current Report
Jan 11, 2024
8-K
Current Report
Jan 08, 2024
10-Q
Quarterly Report
Jan 05, 2024
8-K
Current Report

Peers (Alternatives to AngioDynamics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
207.9B
40.1B
0.08% 5.41%
36.32
5.18
-8.12% -17.45%
71.1B
19.5B
1.90% -2.48%
56.63
3.65
4.02% -22.04%
24.3B
3.8B
13.67% -2.23%
66.92
6.38
-1.48% -28.97%
21.6B
14.9B
3.05% 1.38%
8.13
1.45
2.01% 209.17%
MID-CAP
10.4B
12.7B
2.56% -12.12%
23.32
0.82
0.68% -30.25%
9.9B
2.7B
6.89% -27.73%
-15.56
3.71
-4.68% 82.43%
9.3B
3.5B
8.76% 25.90%
32.8
2.68
4.97% 18.89%
7.2B
3.9B
-8.15% -6.44%
-32.81
1.83
-2.62% 73.16%
3.5B
342.6M
-1.40% 20.18%
-288.8
10.11
42.19% 84.12%
2.7B
6.6B
-4.32% -4.67%
13.36
0.41
2.61% 0.52%
SMALL-CAP
1.0B
3.1B
8.08% -63.68%
-2.4
0.33
7.95% -543.98%
380.2M
163.3M
8.18% -20.52%
-15.47
2.33
7.14% -56.09%
231.2M
329.5M
3.17% -52.24%
-16.38
0.7
0.49% 64.22%
69.6M
50.3M
4.50% -30.54%
-4.59
1.38
3.23% 20.81%
4.5M
3.7M
-15.66% 215.09%
-0.36
1.19
5.77% 8.23%

AngioDynamics Inc News

Latest updates
Yahoo Canada Finance32 hours ago
Zacks Investment Research16 Feb 202412:21 am
Yahoo Finance09 Feb 202408:00 am
Seeking Alpha05 Jan 202408:00 am
Zacks Investment Research05 Jan 202408:00 am

AngioDynamics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue0.5%79,073,00078,679,00091,074,00080,712,00085,429,00081,537,00086,998,00073,970,00078,280,00076,971,00076,842,00071,182,00072,770,00070,216,00058,332,00069,780,00070,003,00066,042,00071,182,00065,524,00069,985,000
Gross Profit0.5%40,262,00040,060,00046,359,00040,504,00045,078,00042,305,00046,455,00038,583,00040,555,00040,139,00042,320,00038,530,00040,174,00035,764,00030,212,00040,299,00041,544,00038,217,00041,332,00038,163,00040,552,000
Operating Expenses1.0%53,382,00052,872,00067,196,00049,432,00053,193,00055,606,00052,852,00043,878,00049,234,00048,239,00063,907,00042,268,00045,010,00040,886,000186,823,00046,535,00044,967,00039,045,00038,398,50041,837,00043,079,000
  S&GA Expenses-7.0%25,464,00027,368,00026,293,00025,406,00026,007,00026,543,00026,833,00020,416,00023,606,00024,446,00023,820,00019,607,00020,174,00017,705,00018,207,00020,934,00020,113,00019,380,00020,775,50018,385,00019,263,000
  R&D Expenses9.0%8,658,0007,941,0007,860,0006,852,0006,838,0008,333,0007,866,0007,280,0008,199,0007,394,0009,104,0008,565,0009,712,0009,009,0007,231,5008,395,0007,764,0006,292,0006,893,0006,915,0007,076,000
EBITDA Margin-20.9%0.060.08-0.06-0.02-0.01-0.010.00-0.05-0.05-0.04-0.03-0.53---------
Interest Expenses-348.7%-534,000-119,000901,000736,000684,000381,000185,000173,000174,000156,000185,000226,000235,000215,000235,000166,00041,000465,0001,410,0001,442,0001,330,000
Income Taxes249.1%16,430,000-11,023,000-398,000-179,000-565,000-853,000-455,000-799,000-512,000-1,636,000-2,471,000-583,000-905,000-545,000158,000-824,000-566,000-116,000-1,365,000-773,000-190,000
Earnings Before Taxes-136.2%-12,618,00034,861,000-21,865,000-9,664,000-9,051,000-13,857,000-6,721,000-5,757,000-8,863,000-8,608,000-21,939,000-4,127,000-5,173,000-4,813,000-156,909,000-6,533,000-3,302,000-1,391,0001,388,500-5,382,000-3,777,000
EBT Margin-65.5%-0.03-0.02-0.16-0.12-0.11-0.11-0.09-0.15-0.14-0.13-0.12-0.63---------
Net Income-163.3%-29,048,00045,884,000-21,467,000-9,485,000-8,486,000-13,004,000-13,004,000-4,958,000-8,351,000-6,972,000-19,468,000-3,544,000-4,268,000-4,268,000-157,067,000-5,709,000-2,736,000-1,275,00058,873,000796,0002,140,000
Net Income Margin-323.2%-0.040.02-0.15-0.13-0.12-0.12-0.11-0.13-0.13-0.12-0.11-0.62---------
Free Cashflow117.7%4,712,000-26,690,00014,898,000704,0006,218,000-25,554,0007,521,000-9,897,000810,000-9,925,00011,579,0004,489,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets1.1%500494533543558558553543554556561582589584594732725690836778784
  Current Assets5.7%185175164153159151143128132131141146150142153129132166315143143
    Cash Equivalents5.7%61.0058.0045.0030.0030.0025.0029.0024.0034.0035.0048.0054.0058.0048.0054.0027.0041.0084.0022842.0043.00
  Inventory7.1%64.0060.0055.0064.0063.0058.0051.0048.0048.0049.0049.0049.0050.0053.0060.0055.0050.0045.0040.0052.0051.00
  Net PPE-1.8%43.0043.0044.0046.0046.0046.0045.0044.0043.0041.0037.0030.0030.0029.0028.0028.0028.0025.0024.0041.0042.00
  Goodwill0.1%15915915920020120120120120220120120120120120135912.0034834842414.00
Liabilities48.8%98.0066.0015414515014412811312212012212713412913912111176.00222224234
  Current Liabilities35.8%78.0057.0084.0070.0074.0066.0074.0049.0054.0052.0058.0050.0046.0040.0051.0049.0057.0047.0073.0053.0050.00
  Long Term Debt---50.00---25.00--------------
    LT Debt, Current-------------------8.006.005.00
Shareholder's Equity-6.2%401428378398408414424430432436439455454455455610614614615554550
  Retained Earnings-17.6%-194-164-210-189-179-171-158-152-147-138-131-112-108-104-10057.0062.0065.0066.008.007.00
  Additional Paid-In Capital0.3%605604599596593590587584580576574571567564562560558556555553549
Shares Outstanding0.0%40.0040.0040.0040.0039.0039.0039.0039.0039.0039.0038.0038.00---------
Float-----450---894---496---531---724
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations120.3%5,266-25,89915,9541,3707,499-24,7458,560-8,7911,941-8,90412,1995,87111,448-5,4253,880-17,8375,937-6,53425,0128,34212,959
  Share Based Compensation-54.7%1,8774,1442,9811,8033,3503,0242,9032,3523,0082,4292,2272,1472,3871,8641,5941,7722,2421,9842,1302,3782,591
Cashflow From Investing-101.8%-1,79398,442-1,528-2,146-2,496-3,576-3,773-2,593-3,849-9,092-9,144-1,382-1,361-1,824-1,479-11,742-48,583-1,541168,427463-48,654
Cashflow From Financing99.4%-352-59,590-94110324,3763299669425,446-9,445-8,022-10.0049124,94715,560--135,749-7,242-10,08153,899

ANGO Income Statement

2023-11-30
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended6 Months Ended
Nov. 30, 2023
Nov. 30, 2022
Nov. 30, 2023
Nov. 30, 2022
Income Statement [Abstract]    
Net sales$ 79,073$ 85,429$ 157,752$ 166,966
Cost of sales (exclusive of intangible amortization)38,81140,35177,43079,583
Gross profit40,26245,07880,32287,383
Operating expenses:    
Research and development8,6586,83816,59915,171
Sales and marketing25,46426,00752,83252,550
General and administrative9,28910,83520,14520,936
Amortization of intangibles3,5624,8087,1879,645
Change in fair value of contingent consideration2211,646911,857
Acquisition, restructuring and other items, net6,1883,0599,4008,640
Total operating expenses53,38253,193106,254108,799
Gain on sale of assets0047,8420
Operating income (loss)(13,120)(8,115)21,910(21,416)
Other expense:    
Interest income (expense), net534(684)653(1,065)
Other expense, net(32)(252)(320)(427)
Total other income (expense), net502(936)333(1,492)
Income (loss) before income tax benefit(12,618)(9,051)22,243(22,908)
Income tax expense (benefit)16,430(565)5,407(1,418)
Net income (loss)$ (29,048)$ (8,486)$ 16,836$ (21,490)
Earnings (loss) per share    
Loss per share, basic (USD per share)$ (0.72)$ (0.21)$ 0.42$ (0.55)
Loss per share, diluted (USD per share)$ (0.72)$ (0.21)$ 0.42$ (0.55)
Weighted average shares outstanding    
Basic weighted average shares outstanding (in shares)40,21939,49040,03039,394
Diluted weighted average shares outstanding (in shares)40,21939,49040,10339,394

ANGO Balance Sheet

2023-11-30
Consolidated Balance Sheets - USD ($)
$ in Thousands
Nov. 30, 2023
May 31, 2023
Current assets  
Cash and cash equivalents$ 60,896$ 44,620
Accounts receivable, net of allowances of $2,240 and $2,150 respectively51,60352,826
Inventories64,25455,325
Prepaid expenses and other8,7154,617
Current assets held for sale06,154
Total current assets185,468163,542
Property, plant and equipment, net42,55744,384
Intangible assets, net103,891111,144
Goodwill159,226159,238
Other assets8,48110,676
Non-current assets held for sale043,653
Total assets499,623532,637
Current liabilities  
Accounts payable37,65040,445
Accrued liabilities29,23726,617
Current portion of contingent consideration9,38714,761
Other current liabilities1,7632,002
Total current liabilities78,03783,825
Long-term debt049,818
Deferred income taxes17,75812,813
Contingent consideration, net of current portion04,535
Other long-term liabilities2,6023,350
Total liabilities98,397154,341
Commitments and contingencies (Note 14)
Stockholders' equity  
Preferred stock, par value $0.01 per share, 5,000,000 shares authorized; no shares issued and outstanding00
Common stock, par value $0.01 per share, 75,000,000 shares authorized; 40,594,406 and 39,981,422 shares issued and 40,224,406 and 39,611,422 shares outstanding at November 30, 2023 and May 31, 2023, respectively383382
Additional paid-in capital605,284599,206
Accumulated deficit(194,019)(210,855)
Treasury stock, 370,000 shares at November 30, 2023 and May 31, 2023, respectively(5,714)(5,714)
Accumulated other comprehensive income(4,708)(4,723)
Total Stockholders’ Equity401,226378,296
Total Liabilities and Stockholders' Equity$ 499,623$ 532,637
ANGO
AngioDynamics, Inc. provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease. The company's thrombus management portfolio includes AlphaVac system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac circuit is indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. In addition, it offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. The company also provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.
 CEO
 WEBSITEwww.angiodynamics.com
 EMPLOYEES815

AngioDynamics Inc Frequently Asked Questions


What is the ticker symbol for AngioDynamics Inc? What does ANGO stand for in stocks?

ANGO is the stock ticker symbol of AngioDynamics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of AngioDynamics Inc (ANGO)?

As of Fri Feb 23 2024, market cap of AngioDynamics Inc is 231.16 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ANGO stock?

You can check ANGO's fair value in chart for subscribers.

What is the fair value of ANGO stock?

You can check ANGO's fair value in chart for subscribers. The fair value of AngioDynamics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of AngioDynamics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ANGO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is AngioDynamics Inc a good stock to buy?

The fair value guage provides a quick view whether ANGO is over valued or under valued. Whether AngioDynamics Inc is cheap or expensive depends on the assumptions which impact AngioDynamics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ANGO.

What is AngioDynamics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Feb 23 2024, ANGO's PE ratio (Price to Earnings) is -16.38 and Price to Sales (PS) ratio is 0.7. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ANGO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on AngioDynamics Inc's stock?

In the past 10 years, AngioDynamics Inc has provided -0.09 (multiply by 100 for percentage) rate of return.